ERBB oncogene proteins as targets for monoclonal antibodies

Related Experiment Video

Updated: May 20, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

O L Polanovski1, E N Lebedenko, S M Deyev

  • 1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.

Biochemistry. Biokhimiia
|July 19, 2012
PubMed

Insights

This study examines the ERBB receptor family

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • The ERBB (Epidermal Growth Factor Receptor) family of tyrosine kinases plays a crucial role in cell signaling.
  • Dysregulation of ERBB receptors is implicated in various cancers, driving tumor growth and progression.
  • Understanding ERBB signaling is vital for developing targeted cancer therapies.

Purpose of the Study:

  • To review the general properties of ERBB receptors and their signaling pathways.
  • To analyze the oncogenic potential of ERBB genes in tumorigenesis.
  • To discuss the therapeutic applications, mechanisms of action, and resistance to anti-ERBB monoclonal antibodies.

Main Methods:

  • Literature review and analysis of existing research on ERBB receptors.
  • Examination of molecular mechanisms underlying ERBB signaling and oncogenesis.
  • Review of clinical data and preclinical studies on anti-ERBB antibody therapies.

Main Results:

  • ERBB receptors are key mediators of signal transduction, crucial in both normal and cancerous cells.
  • Aberrant ERBB signaling contributes significantly to cancer development and progression.
  • Anti-ERBB monoclonal antibodies demonstrate efficacy but face challenges with resistance.

Conclusions:

  • Targeting ERBB receptors with monoclonal antibodies is a validated cancer therapy strategy.
  • Further research into overcoming resistance mechanisms is essential for improving therapeutic outcomes.
  • Development of novel antibody derivatives and combination strategies holds promise for future cancer treatment.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: